Today's Veterinary Business

JUN 2018

Today’s Veterinary Business provides information and resources designed to help veterinarians and office management improve the financial performance of their practices, allowing them to increase the level of patient care and client service.

Issue link:

Contents of this Issue


Page 23 of 77

20 Today's Veterinary Business Business Lessen the risks of product development by working with human industry partners that brought a similar product to market. Similarly, bringing products to mar- ket that used animal models means less time to market and a reduced risk of demonstrating effective- ness. Put another way, "Preclinical work for human therapeutics and diagnostics is done in animals. This is a big de-risking step for animal health," wrote Chris Tam, Ph.D., CEO of Integrated Nanotherapeutics. Working with human health companies that developed similar products removes much of the research and development cost, said Alan Schneyer, Ph.D., CEO and chief scientific officer at Fairbanks Pharmaceuticals. Meet the veterinary com- munity's needs by using products that demonstrated efficacy in human health care. For instance, George Colberg, CEO of Kalos Therapeutics, identified the economic benefits to human and animal companies. "Human health care companies are looking to lever- age large animal studies and un- cover near-future revenue streams," he said. Further, "This opportunity should foster partnership and collab- orations, while providing new prod- ucts to the animal health industry and opportunities to expand sales, revenue and brand share." Expedite the develop- ment of animal health products by using resources available in human health care. Because there is more investment within human health, it "always get[s] the newest and most advanced tech- nologies in both therapeutics and diagnostics" before animal health care, according to Dr. Tam. "Working with human health, animal health can get access to these advanced technologies sooner." Business INNOVATION STATION This past spring, a group gathered in snowy Dedham, Massachusetts, just outside of Boston. The theme of the Human Biotech and Animal Health Business Partnering Summit was the need to explore collaboration between human and animal health. Organized by Kiasco Research, the meeting also highlighted how the veterinary community can benefit. Here's how: SIWA Corp. CEO Lewis Gruber, MS, JD, said: "Partnering with hu- man health care companies [gains the animal health company] access to the cutting edge of technology, which tends to be developed first for treating human ailments even when these ailments are common to animal health care as well." For example, Gruber described this pro- cess at his former company, Arryx Inc.: "Arryx partnered with Genus LLC to use laser tweezer nanobio- technology to sort the sperm of cattle for gender selection to im- prove animal breeding efforts. This collaboration resulted in a commer- cial product provided by Genus." Exploit research that has demonstrated continuity between disease characteristics in both people and animals. Mark Prygocki, CEO of Illustris Phar- maceuticals, sees many synergies in the development of human and animal technologies. His company's 1 permeation technology exploits the similar structures within human and animal tissues. Capitalizing on research that demonstrates these similarities allows Illustris to develop products that would show efficacy in both human and animal health. Kalos' Colberg is developing human cancer drugs and simultane- ously developing a parallel animal health track. These companies are helping to respond to both human and animal needs at the same time. Take advantage of the faster time to market in animal health by developing veterinary products with human companies and then licensing the products in human health care. Fairbanks' Dr. Schneyer said: "From the animal health perspective, taking drugs approved for or under inves- tigation for use in humans provides a much shorter and cost-efficient path to approval for animal use. Toxicology testing has already been accomplished and dosages that are effective without causing side effects are known for humans, so it's rela- tively straightforward to design and execute animal tests to get data for the USDA application for approval." Build Relationships Although some big pharma companies have developed and spun off animal health divisions, Colberg said plenty of opportu- nities are available. The partici- pants outlined three ways to build relationships between human and animal health companies: Establish commercial relevance and market opportunity. Without a product market fit, there is no use exploring further poten- tial. Possible market opportunities come from understanding diseases present in both people and ani- mals. Devoting time to exploring previously unidentified appli- cations across species might be suf- ficient to begin understanding new market opportunities. Part of this process involves looking for unmet needs within an underserved pop- ulation, Colberg said. 2 3 4 1 By Aaron Massecar, MA, Ph.D. Common ground 5 Human biotech leaders would welcome a closer relationship with animal health interests.

Articles in this issue

Archives of this issue

view archives of Today's Veterinary Business - JUN 2018